Product
Ipilimumab + Pembrolizumab + Durvalumab
1 clinical trial
11 indications
Indication
lung cancerIndication
Liver CancerIndication
Colorectal CancerIndication
Pancreatic CancerIndication
Ovarian CancerIndication
Head and Neck CancerIndication
Breast CancerIndication
Stomach CancerIndication
Cervical CancerIndication
Esophageal cancerIndication
SarcomaClinical trial
Triplex CTLA4/PD1/PDL1 Checkpoint Inhibitors Combination Therapy for Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-30